Company intelligence / Profile preview

RetiPharma

Copenhagen, Hovedstaden, Denmarkin.ku.dk ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

RetiPharma is a private Danish biotechnology company developing therapies for degenerative and neurodegenerative eye disorders. The company appears to be focused on neuroprotective peptide-based therapeutics delivered to the eye, with its lead program RP001 being developed for retinal detachment. RetiPharma has described a proprietary in vivo translational platform intended to improve translation from animal models to human disease. Publicly available sources indicate a small private company based in Copenhagen, founded in 2015, and backed by BioInnovation Institute funding. Its pipeline appears to remain at the preclinical stage.

Therapeutic areas: Ophthalmology
Modalities: PeptidesSmall moleculeCell therapy
Industry: Biotech

Partnerships

BioInnovation Institute

Beyond the preview

Go deeper on RetiPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RetiPharma.

Explore the full profile